🔄 Post-Cycle / Recovery & Fertility

What this panel can settle, and by what logic

Nine markers, and the discrimination that justifies the price is between two things a testosterone result cannot tell apart: a restarted axis and a slowly clearing ester.

1. LH & FSH is the recovery measurement; Total Testosterone is not. Exogenous androgen suppresses the gonadotropins and spermatogenesis with them Desai 2022. So a testosterone of 550 ng/dL with an LH of 0.3 IU/L is not recovery, it is residual compound; the same 550 ng/dL with an LH of 4.5 IU/L is a working axis. Low testosterone with high LH is a testicular problem and low testosterone with low LH is a central one, and those go to different clinics Livingston 2023.
2. SHBG (Sex Hormone-Binding Globulin) makes the free testosterone mean something. Calculated free testosterone is only as good as the SHBG behind it, and SHBG swings during and after a cycle, so a free testosterone reported without it is not interpretable Livingston 2023.
3. Prolactin is here because a treatable blocker hides behind it. A raised prolactin suppresses the axis and stalls recovery. Before acting on one, macroprolactin has to be excluded: among people found to have hyperprolactinemia, a meaningful proportion have macroprolactinemia rather than true elevation Sharma 2021, and the two have completely different consequences.
4. Hematocrit on the Complete Blood Count (CBC) with Differential is the timeline check. It should be falling as androgen exposure ends. A hematocrit that is not returning is evidence that something androgenic is still on board.

What it cannot settle, and what would

It cannot tell you what your post-cycle drugs actually contained. Of 601 illicit samples analyzed between 2020 and 2024, 63 were sold as post-cycle therapy drugs. In 34.9% of them the declared active ingredient was not present at all; 20.6% contained neither the declared ingredient nor any other active ingredient, and 14.3% contained only undeclared compounds Blazewicz 2025. That is roughly one in three PCT products that cannot do what it was bought to do. If LH and FSH have not moved after a full protocol, the product failing is at least as likely as your axis failing, and no marker on this panel can distinguish those two.

It cannot tell you whether fertility has returned. Sperm production recovers on a slower and more variable timeline than testosterone does, and there is no reliable blood predictor of who recovers or when Desai 2022. The test is a semen analysis performed to the current WHO manual, which is itself a document with known limitations but is the only instrument there is Boitrelle 2021.

It cannot be read on a single draw. Testosterone carries substantial within-subject biological variation, quantified in the European biological variation study Itkonen 2024, so one value in a recovering axis is a point on a noisy curve. Two morning samples on separate days is the standard before anyone treats Livingston 2023.

And it cannot separate residual ester from endogenous production by concentration alone. Only the gonadotropins do that, which is why they, and not the testosterone, are the reason to buy this panel Desai 2022.

Draw conditions that decide whether the money is wasted

Timing is not a detail on this panel. Drawn too early, all nine markers are true and none of them is about you.

1. Wait out the ester before you draw at all. Long-estered compounds clear over months rather than weeks Desai 2022, and a draw inside that window returns a reassuring testosterone with suppressed gonadotropins, which is the most misread result on this page. If you cannot wait, expect to buy the panel twice.
2. Morning, 7 to 10am, fasted. Testosterone falls across the day and every reference interval it is compared against is a morning one Livingston 2023.
3. Note what you are taking on the request form. Selective estrogen receptor modulators raise LH, FSH and testosterone while they are being taken. A panel drawn during a protocol measures the drug; the panel that answers the question is drawn 4 to 6 weeks after the last dose Livingston 2023.
4. Mass spectrometry for testosterone, sensitive assay for estradiol. This is the recommended methodology and it matters most when the concentrations are unstable Casals 2023. No biotin for 3 days, because LH & FSH, Prolactin and TSH (Thyroid-Stimulating Hormone) are commonly run on streptavidin-based platforms.

How you would know it answered your question, and what each pattern means next

Recovery is measured in months. Four patterns and the interval each one earns.

• LH & FSH in range with Total Testosterone in range: genuine recovery. Confirm it once on a second morning draw 2 to 4 weeks later, because a single testosterone in a recovering axis sits inside meaningful biological variation Itkonen 2024.
• Low LH and FSH with low testosterone 3 months out: the axis has not restarted. Before concluding that, consider the alternative this panel cannot exclude — that the protocol contained nothing active Blazewicz 2025. Either way the next step is an endocrinologist, not a second self-directed round.
• Recovering testosterone but children are in the plan: the blood work has finished answering. Book a semen analysis at 3 to 6 months and repeat it, because sperm parameters vary enough between samples that one is not a conclusion Boitrelle 2021 Desai 2022.
• Raised Prolactin: ask the laboratory for macroprolactin screening before anything is prescribed Sharma 2021. If it is true hyperprolactinemia, it is treatable and it is one of the few genuinely correctable reasons an axis stalls.

Sources read for these sections

• Blazewicz A. Illegal and falsified medicines self-administrated in not approved post-cycle therapy after the cessation of anabolic-androgenic steroids - qualitative analysis. Frontiers in Chemistry 2025 · PMID 40177353
• Desai A, et al. Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic-androgenic steroids (AAS). Therapeutic Advances in Urology 2022 · PMID 35783920
• Boitrelle F, et al. The Sixth Edition of the WHO Manual for Human Semen Analysis: A Critical Review and SWOT Analysis. Life (Basel) 2021 · PMID 34947899
• Livingston M, et al. Adult Male Hypogonadism: A Laboratory Medicine Perspective on Its Diagnosis and Management. Diagnostics (Basel) 2023 · PMID 38132234
• Itkonen O, et al. The European biological variation study (EuBIVAS): Biological variation data for testosterone, follicle stimulating hormone, prolactin, luteinizing hormone and dehydroepiandrosterone sulfate in men. Clinica Chimica Acta 2024 · PMID 38341016
• Sharma LK, et al. Prevalence of Macroprolactinemia in People Detected to Have Hyperprolactinemia. Journal of Laboratory Physicians 2021 · PMID 34975255
• Casals G, et al. Recommendations for the measurement of sexual steroids in clinical practice. A position statement of SEQCML/SEEN/SEEP. Advances in Laboratory Medicine 2023 · PMID 37359897